BMO Capital Maintains Outperform on Eli Lilly and Co, Raises Price Target to $1001
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman has maintained an Outperform rating on Eli Lilly and Co (LLY) and increased the price target from $900 to $1001.
May 01, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Outperform rating is maintained by BMO Capital, with a significant price target increase from $900 to $1001.
The increase in price target by BMO Capital suggests a strong confidence in Eli Lilly's future performance, likely leading to positive investor sentiment and potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100